Axim Biotechnologies Inc  

(Public, OTCMKTS:AXIM)   Watch this stock  
Find more results for AXIM
-0.72 (-7.80%)
Delayed:   12:13PM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 8.15 - 9.15
52 week 0.21 - 19.80
Open 9.15
Vol / Avg. 48,694.00/147,873.00
Mkt cap 438.20M
P/E     -
Div/yield     -
EPS -0.31
Shares 51.49M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -18579.58% -20538.81%
Operating margin -16203.85% -20450.83%
EBITD margin - -20448.55%
Return on average assets -835.97% -1009.24%
Return on average equity - -
CDP Score - -


18 E 50th St Ste 5
NEW YORK, NY 10022-9114
United States - Map
+1-212-7510001 (Phone)
+1-775-7866755 (Fax)

Website links


AXIM Biotechnologies, Inc., formerly Axim International, Inc., is a biotechnology company. The Company is engaged in developing the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids-based products. It is focused on research, development and production of pharmaceutical, nutriceutical and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. It is engaged in the business of research, development and production of alternative and renewable sources of energy, such as high caloric content fuels produced from industrial hemp and from the byproducts of industrial hemp after completion of the oil extraction/decarboxylation process. It is engaged in the research and development of pharmaceutical delivery systems and active pharmaceutical ingredients (API) for treatment of conditions, such as Parkinson's disease, Alzheimer's disease, restless leg syndrome (RLS) and Crohn's disease.